CRISPR Therapeutics AG (CRSP)
Develops gene-editing medicines that fix faulty DNA to treat serious blood disorders and cancers.
$46.46-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-17.2%
The outlook
CRSP is trading near its 52-week lows, well below both its 50- and 200-day moving averages, suggesting a weak near-term trend. Analysts lean positive with a "Buy" consensus, and their average price target sits roughly 86% above the current price, though the stock sits neutral overall on sentiment measures.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 19 analysts
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +86% vs current price
Analyst price target
~12-month · 19 analysts$86.21average target+85.6% vs now
Now $46.46
Low $44.00High $291.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$4.58B
52-wk high
$78.48
52-wk low
$44.12
50-day avg
$52.28
200-day avg
$54.55
Trailing P/E
—